18 hours ago
1
Panama7/iStock Editorial via Getty Images
Sanofi (NASDAQ:SNY) has stopped shipping its anti-cholesterol therapy Praluent, developed with Regeneron (NASDAQ:REGN), as surging demand has caused availability issues, Reuters reported on Tuesday, citing a statement from the French drugmaker.
"The surge in demand has led to limited availability
English (US) ·